...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Avian Pathology >Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination
【24h】

Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination

机译：用土耳其（RHVT-LT）的重组疱疹病毒（RHVT-LT）和鸡胚来源（CEO）疫苗（CEO）疫苗的疫苗接种疫苗接种疫苗接种疫苗（CEO）疫苗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The chicken embryo origin (CEO) infectious laryngotracheitis (ILT) live attenuated vaccines, although capable of protecting against disease and reducing challenge virus replication, can regain virulence. Recombinant ILT vaccines do not regain virulence but are partially successful at blocking challenge virus replication. The objective of this study was to evaluate the effect of rHVT-LT vaccination on CEO replication and how this vaccination strategy enhances protection and limits challenge virus transmission to naive contact chickens. The rHVT-LT vaccine was administered at 1 day of age subcutaneously and the CEO vaccine was administered at 6 weeks of age via eye-drop or drinking water. CEO vaccine replication post vaccination, challenge virus replication and transmission post challenge were evaluated. After vaccination, only the group that received the CEO via eye-drop developed transient conjunctivitis. A significant decrease in CEO replication was detected for the rHVT-LT + CEO groups as compared to groups that received CEO alone. After challenge, reduction in clinical signs and challenge virus replication were observed in all vaccinated groups. However, among the vaccinated groups, the rHVT-LT group presented higher clinical signs and challenge virus replication. Transmission of the challenge virus to naive contact chickens was only observed in the rHVT-LT vaccinated group of chickens. Overall, this study found that priming with rHVT-LT reduced CEO virus replication and the addition of a CEO vaccination provided a more robust protection than rHVT alone. Therefore, rHVT-LT + CEO vaccination strategy constitutes an alternative approach to gain better control of the disease.
机译：鸡胚来源（CEO）传染性喉部阴影炎（ILT）活减毒疫苗，但能够保护疾病和减少攻击病毒复制，可以重新获得毒力。重组ILT疫苗不会恢复毒力，但在阻止攻击病毒复制时部分成功。本研究的目的是评估RHVT-LT疫苗接种对CEO复制的影响以及这种疫苗接种策略如何增强保护和限制攻击病毒传播至幼稚犬鸡。 RHVT-LT疫苗在皮下1天在1天内施用，CEO疫苗通过滴眼或饮用水在6周龄施用。 CEO疫苗复制疫苗接种，挑战病毒复制和传输后挑战进行了评估。疫苗接种后，只有通过肿块发育的瞬时结膜炎获得首席执行官的小组。与单独接受CEO的小组相比，检测到RHVT-LT + CEO组的CEO复制显着降低。在挑战后，在所有接种疫苗中观察到临床症状和挑战病毒复制的减少。然而，在接种疫苗中，RHVT-LT组呈现出更高的临床症状和挑战病毒复制。仅在鸡氏猪的鸡疫苗群中观察到挑战病毒到幼稚的接触鸡。总体而言，该研究发现，用RHVT-LT的引发减少了CEO病毒复制，并且添加了CEO疫苗接种提供比单独的RHVT更强大的保护。因此，RHVT-LT + CEO疫苗接种策略构成了替代方法，以更好地控制该疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号